The present invention relates to new kinase inhibitors, more particularly ROCK inhibitors, compositions comprising such inhibitors, in particular pharmaceuticals, and the use of such inhibitors in the treatment and prevention of diseases. In particular, the present invention relates to new ROCK inhibitors, compositions comprising such inhibitors, in particular pharmaceuticals, and the use of such inhibitors in the treatment and prevention of diseases. In addition, the present invention relates to therapeutic methods and the use of the above compounds in the manufacture of a medicament for application in many therapeutic indications including sexual dysfunction, inflammatory diseases, eye diseases and respiratory diseases. The compounds of the present invention exhibit soft drug properties, i.e., the compounds of the present invention are rapidly inactivated upon entering the systemic circulation. As such, the compounds of the present invention allow for reduced systemic exposure to functionally active ROCK inhibitors. [Chemical 1] [Selection] Figure 1本発明は、新たなキナーゼ阻害剤、より具体的にはROCK阻害剤、かかる阻害剤を含む組成物、特に医薬品、並びに疾患の治療及び予防法におけるかかる阻害剤の使用に関する。特に、本発明は、新たなROCK阻害剤、かかる阻害剤を含む組成物、特に医薬品、並びに疾患の治療及び予防法におけるかかる阻害剤の使用に関する。加えて、本発明は、治療方法、並びに性機能障害、炎症性疾患、眼疾患、及び呼吸器疾患を含む多くの治療適応症への適用のための薬剤の製造における上記化合物の使用に関する。本発明の化合物はソフトドラッグ特性を呈する、すなわち本発明の化合物は体循環に入ると急速に不活性化する。そのため、本発明の化合物は機能的に活性なROCK阻害剤への全身曝露の低減を可能にする。【化１】【選択図】図1
